Article
Chemistry, Medicinal
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Valeria I. Gerasimova, Alexander N. Kornetov, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: This study compared the changes in cytokine levels in schizophrenia patients receiving atypical antipsychotics with or without metabolic syndrome. The results showed that treatment with atypical antipsychotics had different effects on inflammatory cytokine levels depending on the presence of MetS. Patients with MetS experienced increased levels of certain cytokines, while those without MetS had decreased levels of other cytokines after treatment.
Article
Health Care Sciences & Services
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Anastasiia A. Goncharova, Arkadiy Semke, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: Metabolic syndrome (MetS) is a common complication of schizophrenia that is exacerbated by long-term use of antipsychotics. The study found that levels of leptin were significantly increased in MetS patients, while ghrelin levels were significantly decreased. There were fewer significant correlations between ghrelin and other hormones in MetS patients compared to those without MetS.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Psychiatry
Elena G. Kornetova, Alexander N. Kornetov, Irina A. Mednova, Anastasia A. Goncharova, Valeria Gerasimova, Ivan Pozhidaev, Anastasiia S. Boiko, Arkadiy Semke, Anton J. M. Loonen, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: The study reveals significant variations in the prevalence of metabolic syndrome among patients with schizophrenia in different psychiatric hospitals within the same region, highlighting the importance of individualized approaches to minimize the risk of its occurrence based on the specific characteristics of each hospital.
FRONTIERS IN PSYCHIATRY
(2021)
Review
Psychiatry
Marius H. Sneller, Nini de Boer, Sophie Everaars, Max Schuurmans, Sinan Guloksuz, Wiepke Cahn, Jurjen J. Luykx
Summary: Factors associated with metabolic syndrome (MetS) in patients with schizophrenia spectrum disorders using second-generation antipsychotics (SGA) include clinical factors such as age, gender, BMI, SGA exposure, and biochemical factors like hypo-adiponectinemia, elevated CRP levels, and high WBC count. Moreover, a genetic factor, the rs1414334 C-allele of the HTR2C-gene, was found to be associated with MetS in SGA users. Identifying these factors may help predict and prevent MetS in patients using SGAs.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Neurosciences
Mengjuan Xing, Jialing Sheng, Mengxin Cui, Yousong Su, Chengfang Zhang, Xi Chen, Yu Fang, Donghong Cui, Zezhi Li
Summary: This study found that long-term prescriptions of CPZ and CLZ have similar effects on the development of MetS in schizophrenia patients, with the CLZ group showing higher blood pressure levels and a higher incidence of dyslipidemia.
CURRENT NEUROPHARMACOLOGY
(2022)
Review
Endocrinology & Metabolism
Milica M. Borovcanin, Katarina Vesic, Milena Jovanovic, Natasa R. Mijailovic
Summary: Recent studies have suggested that patients with schizophrenia have specific immunometabolic profiles, with elevated levels of Gal-3 potentially linked to antipsychotic treatment and impacting the onset of inflammation, development of obesity, and cognitive changes. Animal studies have shown that downregulation of Gal-3 can be beneficial for insulin regulation of obesity and cognitive preservation. Strategies involving plasma exchange, particularly in the context of Gal-3 elimination, are discussed in this review.
WORLD JOURNAL OF DIABETES
(2021)
Article
Medicine, General & Internal
Po -Yu Chen, Chin-Kuo Chang, Chun-Hsin Chen, Su-Chen Fang, Valeria Mondelli, Chih-Chiang Chiu, Mong-Liang Lu, Ling-Ling Hwang, Ming-Chyi Huang
Summary: This study compared the levels of orexin-A and metabolic profiles in drug-free patients, aripiprazole-treated patients, and clozapine-treated patients with schizophrenia. The results showed that patients under antipsychotic drug treatment had increased orexin-A levels compared to drug-free patients, with the aripiprazole-treated group having higher orexin-A levels than the clozapine-treated group. Higher orexin-A levels were associated with reduced risks of metabolic syndrome and type 2 diabetes mellitus. Even after adjusting for the effects of metabolic problems, antipsychotic drug treatment was still associated with orexin-A regulation, with aripiprazole having a more significant effect than clozapine. This suggests that antipsychotic drugs have an independent effect on orexin-A levels, and the effect may vary depending on the drug's obesogenicity.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Health Care Sciences & Services
Diana Z. Paderina, Anastasiia S. Boiko, Ivan V. Pozhidaev, Anna V. Bocharova, Irina A. Mednova, Olga Yu. Fedorenko, Elena G. Kornetova, Anton J. M. Loonen, Arkadiy V. Semke, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: The study investigated the association of nine polymorphisms in serotonergic system genes with MetS in patients with schizophrenia. Results suggested that allelic variants of HTR2C genes may affect metabolic parameters, and MetS is too complex to be studied without dissecting it into individual components.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Review
Endocrinology & Metabolism
Ting Yao, Jiehui He, Zhicheng Cui, Ruwen Wang, Kaixuan Bao, Yiru Huang, Ru Wang, Tiemin Liu
Summary: 5-HTR2C plays a key role in regulating energy homeostasis and metabolic disorders, with potential therapeutic implications in anti-obesity drugs. Understanding the neural circuits and molecular pathways of 5-HTR2C signaling is crucial for developing effective treatment strategies. Additionally, the interaction between 5-HTR2C and other metabolic hormones, such as leptin and insulin, is an important area of research.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Psychiatry
Brian O'Donoghue, Nathan Mifsud, Emily Castagnini, Alison Langstone, Andrew Thompson, Eoin Killackey, Patrick McGorry
Summary: Background factors such as obesity, smoking, and sedentary behavior contribute to early mortality in psychotic disorders. However, adding a physical health nurse to the care of young people with first-episode psychosis did not prevent clinically significant weight gain, smoking, metabolic syndrome, or sedentary behavior. This suggests that more intensive interventions are needed.
Review
Clinical Neurology
Xuemei Liao, Hui Ye, Tianmei Si
Summary: Metabolic syndrome occurs more frequently in patients with schizophrenia than in the general population, with antipsychotic medication being a primary risk factor. Different antipsychotics may have different impacts on glucose and lipid metabolism due to their pharmacological affinity to MetS-related receptors, and switching to lower metabolic risk antipsychotics may improve patients' metabolic parameters. This review aims to discuss strategies for switching antipsychotic medications and their impact on metabolic abnormalities in patients with schizophrenia.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Article
Clinical Neurology
Michael Tocco, John W. Newcomer, Yongcai Mao, Andrei Pikalov, Antony Loebel
Summary: The study evaluated the impact of lurasidone treatment on the risk of metabolic syndrome in patients with schizophrenia, showing that the risk of developing MetS in patients treated with lurasidone was minimal in both short-term and long-term use.
Review
Biochemistry & Molecular Biology
Kah Kheng Goh, Cynthia Yi-An Chen, Tzu-Hua Wu, Chun-Hsin Chen, Mong-Liang Lu
Summary: The high prevalence of metabolic syndrome in persons with schizophrenia has led to investigations into the common pathways connecting these two conditions, which may be underpinned by oxytocin system dysfunction. Current evidence suggests the existence of overlapping neurobiological features between metabolic risk factors and psychiatric symptoms, highlighting the potential role of oxytocin in understanding the pathogenesis of schizophrenia and metabolic syndrome.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Psychiatry
Nousayhah Amdanee, Miaomiao Shao, Xiuxiu Hu, Xinyu Fang, Chao Zhou, Jiu Chen, Mohammad Ridwan Chattun, Lu Wen, Xinming Pan, Xiangrong Zhang, Yue Xu
Summary: This study found that AP-induced constipation is associated with disturbances in specific metabolic pathways and alterations in the gut microbiome. These findings provide mechanistic insights into AP-induced constipation.
SCHIZOPHRENIA BULLETIN
(2023)
Review
Psychiatry
Katherine R. H. Mortimer, Mohammed Zia Ul Haq Katshu, Lisa Chakrabarti
Summary: Psychosis and the use of second-generation antipsychotics (SGAs) are risk factors for developing metabolic syndrome (MetS). SGAs worsen metabolic abnormalities, leading to increased risks of severe weight gain, type 2 diabetes, and cardiovascular disease. Mitochondrial dysfunction is a hallmark of MetS, but the mechanisms through which SGAs induce MetS and how mitochondria are involved in this process are still unclear.
FRONTIERS IN PSYCHIATRY
(2023)
Article
Psychiatry
M. van Nierop, M. Bak, R. de Graaf, M. ten Have, S. van Dorsselaer, R. van Winkel
ACTA PSYCHIATRICA SCANDINAVICA
(2016)
Article
Psychiatry
J. de Nijs, M. A. Pet
ACTA PSYCHIATRICA SCANDINAVICA
(2016)
Article
Genetics & Heredity
Tim B. Bigdeli, Stephan Ripke, Silviu-Alin Bacanu, Sang Hong Lee, Naomi R. Wray, Pablo V. Gejman, Marcella Rietschel, Sven Cichon, David St Clair, Aiden Corvin, George Kirov, Andrew McQuillin, Hugh Gurling, Dan Rujescu, Ole A. Andreassen, Thomas Werge, Douglas H. R. Blackwood, Carlos N. Pato, Michele T. Pato, Anil K. Malhotra, Michael C. O'Donovan, Kenneth S. Kendler, Ayman H. Fanous
AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
(2016)
Article
Psychology, Clinical
A. Vreeker, M. P. M. Boks, L. Abramovic, S. Verkooijen, A. H. van Bergen, M. H. J. Hillegers, A. T. Spijker, E. Hoencamp, E. J. Regeer, R. F. Riemersma-Van der Lek, A. W. M. M. Stevens, P. F. J. Schulte, R. Vonk, R. Hoekstra, N. J. M. van Beveren, R. W. Kupka, R. M. Brouwer, C. E. Bearden, J. H. MacCabe, R. A. Ophoff
PSYCHOLOGICAL MEDICINE
(2016)
Article
Psychiatry
Suzanne Medema, Roel J. T. Mocking, Maarten W. J. Koeter, Frederic M. Vaz, Carin Meijer, Lieuwe de Haan, Nico J. M. van Beveren, Rene Kahn, Jim van Os, Durk Wiersma, Richard Bruggeman, Wiepke Cahn, Inez Myin-Germeys
SCHIZOPHRENIA BULLETIN
(2016)
Article
Psychiatry
F. Schirmbeck, M. Swets, C. J. Meijer, M. Zink, L. de Haan, Rene S. Kahn, Wiepke Cahn, Jim van Os, Inez Myin-Germeys, Richard Bruggeman, Agna A. Bartels-Velthuis
ACTA PSYCHIATRICA SCANDINAVICA
(2016)
Article
Psychiatry
Laura A. Steenhuis, Agna A. Bartels-Velthuis, Jack A. Jenner, Andre Aleman, Richard Bruggeman, Maaike H. Nauta, Gerdina H. M. Pijnenborg
PSYCHIATRY RESEARCH
(2016)
Article
Psychiatry
Henriette D. Heering, Neeltje E. M. van Haren
PSYCHIATRY RESEARCH
(2016)
Article
Psychiatry
Henriette Dorothee Heering, Saskia Goedhart, Richard Bruggeman, Wiepke Cahn, Lieuwe de Haan, Rene S. Kahn, Carin J. Meijer, Inez Myin-Germeys, Jim van Os, Durk Wiersma
Article
Psychiatry
Edith J. Liemburg, Jojanneke Bruins, Nico van Beveren, Md. Atiqul Islam, Behrooz Z. Alizadeh
SCHIZOPHRENIA RESEARCH
(2016)
Article
Psychiatry
Anastasia Lim, Hans W. Hoek, Mathijs L. Deen, Jan Dirk Blom
SCHIZOPHRENIA RESEARCH
(2016)
Article
Psychiatry
Mayke Janssens, Lindy-Lou Boyette, Henriette D. Heering, Agna A. Bartels-Velthuis, Tineke Lataster, Rene S. Kahn, Lieuwe de Haan, Jim van Os, Durk Wiersma, Richard Bruggeman, Wiepke Cahn, Carin Meijer, Inez Myin-Germeys
SCHIZOPHRENIA RESEARCH
(2016)
Article
Psychiatry
Divya Mehta, Felix C. Tropf, Jacob Gratten, Andrew Bakshi, Zhihong Zhu, Silviu-Alin Bacanu, Gibran Hemani, Patrik K. E. Magnusson, Nicola Barban, Tonu Esko, Andres Metspalu, Harold Snieder, Bryan J. Mowry, Kenneth S. Kendler, Jian Yang, Peter M. Visscher, John J. McGrath, Melinda C. Mills, Naomi R. Wray, S. Hong Lee
Article
Behavioral Sciences
Sanne C. T. Peeters, Ed H. B. M. Gronenschild, Therese van Amelsvoort, Jim van Os, Machteld Marcelis
BRAIN AND BEHAVIOR
(2016)
Review
Psychiatry
Andre Aleman, Tania M. Lincoln, Richard Bruggeman, Ingrid Melle, Johan Arends, Celso Arango, Henderikus Knegtering
SCHIZOPHRENIA RESEARCH
(2017)